STAT+: Biotech execs, academic expert lament impact of FDA turnover on rare disease drug development
statnews.com·May 20, 2026
Executives in the drug industry expressed concerns at the STAT Breakthrough Summit West about the recent upheaval at the FDA, which has led to anxiety among rare disease drug developers regarding the approval process and investor confidence. Mahzi Therapeutics CEO Yael Weiss highlighted that her investors are increasingly worried about how these changes will impact the future of their drug approvals.
The recent upheaval at the FDA is causing significant concern among biotech executives, particularly regarding the approval process for rare disease drugs. This uncertainty may impact investment strategies and decision-making for companies in these sectors, highlighting the need for vigilance and potential contingency planning.